Cargando…

Increase in the Immune Response in Balb/c Mice after the Co-Administration of a Vector-Based COVID-19 Vaccine with Cytosine Phosphoguanine Oligodeoxynucleotide

The effects of cytosine phosphoguanine oligodeoxynucleotides (CPG ODNs) on immune response have been demonstrated for different vaccines; however, such information is limited for the vector-based Coronavirus disease 2019 (COVID-19). This paper aims to demonstrate the potential effect of CPG ODNs on...

Descripción completa

Detalles Bibliográficos
Autores principales: Celise, Divine Ainee, Kimotho, James, Kimani, Josephine W., Muriithi, Alex Kigundu, Odari, Eddy Okoth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864427/
https://www.ncbi.nlm.nih.gov/pubmed/36679896
http://dx.doi.org/10.3390/vaccines11010053
_version_ 1784875582099554304
author Celise, Divine Ainee
Kimotho, James
Kimani, Josephine W.
Muriithi, Alex Kigundu
Odari, Eddy Okoth
author_facet Celise, Divine Ainee
Kimotho, James
Kimani, Josephine W.
Muriithi, Alex Kigundu
Odari, Eddy Okoth
author_sort Celise, Divine Ainee
collection PubMed
description The effects of cytosine phosphoguanine oligodeoxynucleotides (CPG ODNs) on immune response have been demonstrated for different vaccines; however, such information is limited for the vector-based Coronavirus disease 2019 (COVID-19). This paper aims to demonstrate the potential effect of CPG ODNs on immunological response against the vector-based COVID-19 vaccine on Balb/c mice using a JNJ-78436735 Ad26.COV2-S recombinant as a model vaccine. A total of 18 BALB/c mice clustered into six groups were used. All groups were observed for 14- and 28-days post immunization. Qualitative determination of IgG was performed using indirect Enzyme-Linked Immunosorbent Assay (ELISA) and qPCR for cytokine profiling. A significant (p ≤ 0.001) rise in antibody response was observed for groups 3 and 4, who also showed increased expression levels of Tumor Necrosis Factor (TNF) and Interferon Gamma (IFN-γ). Immunological parameters for toxicity were normal in all treatment groups. We conclude that supplementing vector-based COVID-19 vaccines with CpG ODNs has the potential to boost the body’s immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
format Online
Article
Text
id pubmed-9864427
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98644272023-01-22 Increase in the Immune Response in Balb/c Mice after the Co-Administration of a Vector-Based COVID-19 Vaccine with Cytosine Phosphoguanine Oligodeoxynucleotide Celise, Divine Ainee Kimotho, James Kimani, Josephine W. Muriithi, Alex Kigundu Odari, Eddy Okoth Vaccines (Basel) Article The effects of cytosine phosphoguanine oligodeoxynucleotides (CPG ODNs) on immune response have been demonstrated for different vaccines; however, such information is limited for the vector-based Coronavirus disease 2019 (COVID-19). This paper aims to demonstrate the potential effect of CPG ODNs on immunological response against the vector-based COVID-19 vaccine on Balb/c mice using a JNJ-78436735 Ad26.COV2-S recombinant as a model vaccine. A total of 18 BALB/c mice clustered into six groups were used. All groups were observed for 14- and 28-days post immunization. Qualitative determination of IgG was performed using indirect Enzyme-Linked Immunosorbent Assay (ELISA) and qPCR for cytokine profiling. A significant (p ≤ 0.001) rise in antibody response was observed for groups 3 and 4, who also showed increased expression levels of Tumor Necrosis Factor (TNF) and Interferon Gamma (IFN-γ). Immunological parameters for toxicity were normal in all treatment groups. We conclude that supplementing vector-based COVID-19 vaccines with CpG ODNs has the potential to boost the body’s immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. MDPI 2022-12-26 /pmc/articles/PMC9864427/ /pubmed/36679896 http://dx.doi.org/10.3390/vaccines11010053 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Celise, Divine Ainee
Kimotho, James
Kimani, Josephine W.
Muriithi, Alex Kigundu
Odari, Eddy Okoth
Increase in the Immune Response in Balb/c Mice after the Co-Administration of a Vector-Based COVID-19 Vaccine with Cytosine Phosphoguanine Oligodeoxynucleotide
title Increase in the Immune Response in Balb/c Mice after the Co-Administration of a Vector-Based COVID-19 Vaccine with Cytosine Phosphoguanine Oligodeoxynucleotide
title_full Increase in the Immune Response in Balb/c Mice after the Co-Administration of a Vector-Based COVID-19 Vaccine with Cytosine Phosphoguanine Oligodeoxynucleotide
title_fullStr Increase in the Immune Response in Balb/c Mice after the Co-Administration of a Vector-Based COVID-19 Vaccine with Cytosine Phosphoguanine Oligodeoxynucleotide
title_full_unstemmed Increase in the Immune Response in Balb/c Mice after the Co-Administration of a Vector-Based COVID-19 Vaccine with Cytosine Phosphoguanine Oligodeoxynucleotide
title_short Increase in the Immune Response in Balb/c Mice after the Co-Administration of a Vector-Based COVID-19 Vaccine with Cytosine Phosphoguanine Oligodeoxynucleotide
title_sort increase in the immune response in balb/c mice after the co-administration of a vector-based covid-19 vaccine with cytosine phosphoguanine oligodeoxynucleotide
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864427/
https://www.ncbi.nlm.nih.gov/pubmed/36679896
http://dx.doi.org/10.3390/vaccines11010053
work_keys_str_mv AT celisedivineainee increaseintheimmuneresponseinbalbcmiceafterthecoadministrationofavectorbasedcovid19vaccinewithcytosinephosphoguanineoligodeoxynucleotide
AT kimothojames increaseintheimmuneresponseinbalbcmiceafterthecoadministrationofavectorbasedcovid19vaccinewithcytosinephosphoguanineoligodeoxynucleotide
AT kimanijosephinew increaseintheimmuneresponseinbalbcmiceafterthecoadministrationofavectorbasedcovid19vaccinewithcytosinephosphoguanineoligodeoxynucleotide
AT muriithialexkigundu increaseintheimmuneresponseinbalbcmiceafterthecoadministrationofavectorbasedcovid19vaccinewithcytosinephosphoguanineoligodeoxynucleotide
AT odarieddyokoth increaseintheimmuneresponseinbalbcmiceafterthecoadministrationofavectorbasedcovid19vaccinewithcytosinephosphoguanineoligodeoxynucleotide